Business Context and Reporting Period
This Form 8-K Current Report was filed by Corvus Pharmaceuticals, Inc. on December 12, 2019. The filing addresses Item 5.02 regarding the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. Specifically, the Board of Directors approved 2020 annual base salaries and stock option awards for key executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
On December 12, 2019, the Board approved the following 2020 compensation packages for named executive officers under the 2016 Equity Incentive Award Plan. Stock options vest in equal monthly installments over 48 months, subject to continued service:
- Richard A. Miller, M.D. (CEO): $300,000 annual base salary; 320,000 stock option shares.
- Leiv Lea (CFO): $360,500 annual base salary; 160,000 stock option shares.
- Joseph J. Buggy, Ph.D. (EVP, Discovery Research): $200,000 annual base salary; 40,000 stock option shares.
The exercise price for the stock options was set equal to the closing price of the Company's common stock on The Nasdaq Global Market on the date of grant.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The only noted condition for the awards is continued service as of each vesting date.
Investor Verification Checklist
- Verify the closing stock price on December 12, 2019, to determine the exercise price of the granted options.
- Confirm the total number of shares available under the 2016 Equity Incentive Award Plan to assess remaining capacity.
- Review the Company's most recent 10-K or 10-Q for context on cash burn and liquidity relative to these new compensation obligations.
- Check for any subsequent filings regarding changes to the vesting schedule or executive departures.